Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial.
Adolescent
Adult
Cross-Over Studies
Diet
/ methods
Dietary Fiber
/ pharmacology
Fatty Acids, Unsaturated
/ pharmacology
Female
Gastrointestinal Microbiome
/ drug effects
Humans
Male
Metabolic Syndrome
/ metabolism
Middle Aged
Oligosaccharides
Overweight
/ metabolism
Xylans
/ pharmacology
Young Adult
Arabinoxylan oligosaccharide
Fiber
Fish oil
Gut microbiota
Metabolic syndrome
Obesity
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
06
02
2018
revised:
04
01
2019
accepted:
13
01
2019
pubmed:
5
3
2019
medline:
4
5
2021
entrez:
5
3
2019
Statut:
ppublish
Résumé
Gut microbiota composition is linked to obesity and metabolic syndrome. The nutrients and doses required to modulate the gut microbiota towards beneficially influence components of the metabolic syndrome are unclear. This study aimed to investigate diet-induced effects on the gut microbiota and metabolic markers in overweight individuals with indices of the metabolic syndrome. A twelve-week randomized cross-over trial was conducted with two intervention periods separated by a washout period. The dietary intakes of interest were wheat bran extract, rich in arabinoxylan oligosaccharides (AXOS) (10.4 g/d AXOS) and polyunsaturated fatty acids (PUFA) (3.6 g/d n-3 PUFA). Dietary records, fecal and blood samples, as well as anthropometric data, were collected before and after intervention. Anthropometry and gastrointestinal symptoms were evaluated weekly. Gut microbiota composition was analyzed by massive sequencing of 16S ribosomal RNA gene V3V4 amplicons. Twenty-seven participants completed the study (90%). Intake of AXOS induced an expected bifidogenic effect on gut microbiota (p < 0.01) and increased butyrate-producing bacterial species as well (p < 0.05). Beta-diversity analysis indicated that the structure of the gut microbiota only changed as a result of the AXOS intervention (Permanova = 1.90, p < 0.02) and no changes in metabolic markers were observed after any of the interventions. AXOS intake has a bifidogenic effect and also increases butyrate producers in the gut microbiota; even though this type of dietary fiber did not modulate lipid or glucose metabolic parameters related to metabolic syndrome. Four-week PUFA intake did not induce any notable effect on the gut microbiota composition or metabolic risk markers. Registered under ClinicalTrials.gov Identifier no. NCT02215343. Registered at https://www.clinicaltrials.gov/ (NCT02215343). H-4-2014-052. 2013-54-0522.
Sections du résumé
BACKGROUND & AIMS
Gut microbiota composition is linked to obesity and metabolic syndrome. The nutrients and doses required to modulate the gut microbiota towards beneficially influence components of the metabolic syndrome are unclear. This study aimed to investigate diet-induced effects on the gut microbiota and metabolic markers in overweight individuals with indices of the metabolic syndrome.
METHODS
A twelve-week randomized cross-over trial was conducted with two intervention periods separated by a washout period. The dietary intakes of interest were wheat bran extract, rich in arabinoxylan oligosaccharides (AXOS) (10.4 g/d AXOS) and polyunsaturated fatty acids (PUFA) (3.6 g/d n-3 PUFA). Dietary records, fecal and blood samples, as well as anthropometric data, were collected before and after intervention. Anthropometry and gastrointestinal symptoms were evaluated weekly. Gut microbiota composition was analyzed by massive sequencing of 16S ribosomal RNA gene V3V4 amplicons.
RESULTS
Twenty-seven participants completed the study (90%). Intake of AXOS induced an expected bifidogenic effect on gut microbiota (p < 0.01) and increased butyrate-producing bacterial species as well (p < 0.05). Beta-diversity analysis indicated that the structure of the gut microbiota only changed as a result of the AXOS intervention (Permanova = 1.90, p < 0.02) and no changes in metabolic markers were observed after any of the interventions.
CONCLUSIONS
AXOS intake has a bifidogenic effect and also increases butyrate producers in the gut microbiota; even though this type of dietary fiber did not modulate lipid or glucose metabolic parameters related to metabolic syndrome. Four-week PUFA intake did not induce any notable effect on the gut microbiota composition or metabolic risk markers.
REGISTRATION
Registered under ClinicalTrials.gov Identifier no. NCT02215343.
CLINICAL TRIAL REGISTRATION
Registered at https://www.clinicaltrials.gov/ (NCT02215343).
ETHICAL COMMITTEE
H-4-2014-052.
THE DANISH DATA PROTECTION AGENCY
2013-54-0522.
Identifiants
pubmed: 30827722
pii: S0261-5614(19)30030-5
doi: 10.1016/j.clnu.2019.01.012
pii:
doi:
Substances chimiques
Dietary Fiber
0
Fatty Acids, Unsaturated
0
Oligosaccharides
0
Xylans
0
arabinoxylan
9040-27-1
Banques de données
ClinicalTrials.gov
['NCT02215343']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-79Informations de copyright
Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.